Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN)

被引：0
|
作者：
Glisson, Bonnie S.
Tseng, Jennifer
Marur, Shanthi
Shin, Dong M.
Murphy, Barbara A.
Cohen, Ezra E. W.
Thomas, Christopher Y.
Willey, Richard
Cosaert, Jan
William, William Nassib
Harun, Nusrat
Lee, J. Jack
Haddad, Robert I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Orlando, FL USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Vanderbilt Univ Sch Med, Deptartment Med, Nashville, TN USA
[6] Univ Chicago Med Ctr, Chicago, IL USA
[7] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[8] ImClone Syst LLC, Bridgewater, NJ USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[10] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6030
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cetuximab, Fluorouracil (5-FU), Ciplatin and Docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCID).
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher-Williams, J.
    Gruenwald, V
    Rethwisch, V.
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2013, 36 : 94 - 94
  • [42] Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial
    Fayette, J.
    Bauman, J.
    Salas, S.
    Colevas, D.
    Even, C.
    Cupissol, D.
    Posner, M. R.
    Lefebvre, G.
    Saada-Bouzid, E.
    Bernadach, M.
    Seiwert, T.
    Pearson, A.
    Messouak, S.
    Cornen, S. L.
    Andre, P.
    Rotolo, F.
    Boyer-Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1450 - S1450
  • [43] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [44] Interim Results of a Phase II Trial of Concurrent Cetuximab and Stereotactic Body Radiotherapy (SBRT) for Recurrent Squamous Cell Carcinomas of the Head and Neck (SCCHN)
    Heron, D.
    Ferris, R. L.
    Burton, S.
    Kubicek, G.
    Gibson, M.
    Gooding, W.
    Argiris, A.
    Quinn, A.
    Huq, M. S.
    Ozhasoglu, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S105 - S105
  • [45] Palliative chemotherapy (CT) with or without cetuximab (CTX) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An Indian retrospective analysis
    Bahl, A.
    Choudhary, P.
    Bhatia, K.
    Singhla, S.
    Shrivastava, G.
    Bal, J.
    Anand, A. K.
    Chaturvedi, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Kochanny, Sara E.
    Worden, Francis P.
    Adkins, Douglas R.
    Lim, Dean W.
    Bauman, Julie E.
    Wagner, Stephanie A.
    Brisson, Ryan J.
    Karrison, Theodore G.
    Stadler, Walter M.
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    CANCER, 2020, 126 (10) : 2146 - 2152
  • [47] A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).
    Sabichi, A. L.
    Kies, M. S.
    Glisson, B. S.
    Lu, C.
    Ginsberg, L. E.
    Bartos, C. I.
    Feng, L.
    Tran, H. T.
    Lippman, S. M.
    Blumenschein, G. R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Degardin, M
    Bastit, P
    Rolland, F
    Armand, JP
    Chevallier, B
    VanGlabbeke, M
    Boudillet, J
    Tresca, P
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 843 - 843
  • [49] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
    Guigay, J.
    Fayette, J.
    Dillies, A.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. H.
    Zanetta, S.
    Pointreau, Y.
    Le Moal, L. Bozec
    Ribere, L. Brugel
    Henry, S.
    Temam, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara
    Tanvetyanon, Tawee
    Leon, Marino E.
    Hayes, D. Neil
    Haigentz, Missak, Jr.
    Saba, Nabil
    Nieva, Jorge
    Bishop, Justin
    Sidransky, David
    Ravi, Rajani
    Bedi, Atul
    Chung, Christine H.
    ORAL ONCOLOGY, 2015, 51 (04) : 376 - 382
12345